In a CT26 colon cancer mouse model, immunotherapy applied in combination with VISTA and PD-L1 ICIs contributed to tumor regression and led to long-term survival in the mouse model, demonstrating the rationale for targeting VISTA in cancer immunotherapy. The gene discussed is CD274; the disease is malignant colon neoplasm.